A health worker prepares a dose of the Oxford-AstraZeneca vaccine.
This mechanism was established in 2001, and it allows the countries of the European Union to participate in the coordination of their assistance and the deployment of resources around the world in the event of a large-scale emergency that can not be handled by a specific country on its own.
"The Commission has started last Friday a legal action against the company AstraZeneca on the basis of breaches of the advanced purchase agreement", European Union spokesman Stefan De Keersmaecker said.
Brussels has said that discussions on possible global vaccine certificates are continuing, which could take the form of an official government vaccination certificate issued by the traveller's own country, which would then be accepted by other nations.
De Keersmaecker said the deal between the European Union and AstraZeneca had "not been respected" and accused the pharmaceuticals company of failing to "come up with a reliable strategy to ensure the timely delivery of doses".
The number of blood clot or thrombosis cases after receiving the AstraZeneca Covid-19 vaccine jab is low and rare, said the Health Ministry's (MOH) Covid-19 Vaccine Candidate Selection Sub-Committee (JKKPCV) chairman, Dr Kalaiarasu M Periasamy. AstraZeneca agreed to deliver around 100 million doses of its vaccine to the European Union in the first quarter of 2021.
The shortfall has contributed to the slow vaccination campaign across Europe, which has lagged both the United Kingdom and US.
The European Commission has said it is working on a digital health pass that "will be finished by mid-May".
The EU believes AstraZeneca has been unfairly and illegally routing jabs to the United Kingdom at the expense of Europe.
The contract indicated that the company would use "best reasonable efforts" to meet targets.
The European Commission confirmed it began legal proceedings against AstraZeneca for its vaccine-delivery shortages.
British-Swedish firm AstraZeneca dismissed the legal action as "without merit" and insisted "we welcome this opportunity to resolve this dispute as soon as possible".
"AstraZeneca has fully complied with the Advance Purchase Agreement with the European Commission and will strongly defend itself in court", the company wrote.
The company also acknowledged that they have faced "manufacturing challenges".